Development of High-Value-Added Disposable Catheters
First written in FY2016. 27 of 35 entries say "Restated". Latest entry: 2026-07-30.
5 other companies' latest entry also says "Advanced".
- 2026-07-30AdvancedEarnings
「Selling, general and administrative expenses increased as we accelerated R&D activities related to new product development and the global optimization of in-house products as investments for future growth, resulting in higher revenue but lower operating profit for the first quarter cumulative consolidated period.」
The acceleration of R&D activities, including for PFA systems, was reflected in higher expenses and affected performance. - FY2026AdvancedAnnual report
「The company also entered into a strategic partnership with CardioFocus and is advancing the development of PFA catheter products. By combining the company's manufacturing technology with CardioFocus's clinical and equipment expertise, the companies are preparing for the global launch of competitive PFA products.」
PFA-related efforts progressed to product development and preparations for a global launch under the strategic partnership with CardioFocus. - 2026-05-07AdvancedEarnings
「We have incorporated an acceleration of strategic R&D investment related to PFA and the development of overseas markets as an expense item for medium- to long-term growth.」
The company indicated that it would accelerate R&D investment related to PFA and overseas market development. - FY2025AdvancedAnnual report
「In February 2025, the company entered into a strategic partnership with CardioFocus, which has its own PFA system, to jointly develop PFA products and supply them to global markets.」
R&D on high-value-added catheters progressed to a specific external collaboration with CardioFocus, involving joint development and a global supply agreement for products using PFA technology. - FY2025-H1RestatedAnnual report
「The amount spent on R&D during the interim consolidated period was ¥1,127 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated period.」
The company disclosed interim-period R&D expenses of ¥1,127 million, stating that there had been no material changes in its R&D activities. - FY2024-Q3RestatedAnnual report
「The amount spent on R&D during the cumulative third quarter was ¥1,670 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company disclosed R&D expenses of ¥1,670 million for the cumulative third quarter, stating that there had been no material changes in its R&D activities. - FY2024-Q2RestatedAnnual report
「The amount spent on R&D during the cumulative second quarter was ¥1,078 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
There were no material changes in the policy of focusing R&D on high-value-added catheters and artificial blood vessels, and R&D expenses for the cumulative second quarter totaled ¥1,078 million. - FY2024-Q1RestatedAnnual report
「The amount spent on R&D during the cumulative first quarter was ¥502 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
The company disclosed R&D expenses of ¥502 million for the first quarter, stating that there had been no material changes in its R&D activities. - FY2023AdvancedAnnual report
「As a result, the company recorded R&D expenses of ¥2,316 million for the fiscal year.」
The company continued R&D on high-value-added catheters, artificial blood vessels, gastrointestinal products and catheters for regenerative medicine, bringing R&D expenses for the fiscal year to ¥2,316 million. - FY2023-Q3RestatedAnnual report
「The amount spent on R&D during the cumulative third quarter was ¥1,708 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company disclosed R&D expenses of ¥1,708 million for the cumulative third quarter, stating that there had been no material changes in its R&D activities. - FY2023-Q2RestatedAnnual report
「The amount spent on R&D during the cumulative second quarter was ¥1,131 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The company disclosed R&D expenses of ¥1,131 million for the cumulative second quarter, stating that there had been no material changes in its R&D activities. - FY2022AdvancedAnnual report
「The company recorded R&D expenses of ¥2,159 million for the fiscal year. In addition, it entered into an agreement with Galvanize Therapeutics in the United States in May 2021 to supply the company-developed catheter for pulsed field ablation, a next-generation cardiac ablation technology.」
The company recorded R&D expenses of ¥2,159 million, and made progress in external commercialization and productization of its R&D results, including the launch of ShockATα, a supply agreement for catheters for pulsed field ablation, and the development of gastrointestinal products. - FY2022-Q3RestatedAnnual report
「The amount spent on R&D during the cumulative third quarter was ¥1,507 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company disclosed R&D expenses of ¥1,507 million for the cumulative third quarter, stating that there had been no material changes in its R&D activities. - FY2022-Q2RestatedAnnual report
「The amount spent on R&D during the cumulative second quarter was ¥972 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The company disclosed R&D expenses of ¥972 million for the cumulative second quarter, stating that there had been no material changes in its R&D activities. - FY2022-Q1RestatedAnnual report
「The amount spent on R&D during the cumulative first quarter was ¥425 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
The company recorded R&D expenses of ¥425 million and reaffirmed that there had been no material changes in its R&D activities. - FY2021AdvancedAnnual report
「In February 2021, the company launched ShockATα, a new-generation generator for the BeeAT intracardiac defibrillation catheter, with improved performance over the previous model.」
The company reported a specific achievement under its policy of focusing R&D on high-value-added disposable catheters and related equipment: the launch of a next-generation generator for BeeAT. - FY2021-Q3RestatedAnnual report
「The amount spent on R&D during the cumulative second quarter was ¥1,273 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
There were no material changes in the R&D policy, and R&D expenses for the cumulative third quarter totaled ¥1,273 million. - FY2021-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter were ¥801 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter.」
The company disclosed R&D expenses of ¥801 million for the cumulative second quarter, stating that there had been no material changes in its R&D activities. - FY2020RestatedAnnual report
「The group aims to develop high-value-added disposable catheter products and their generators, console products, artificial blood vessels, open stent grafts and other vascular treatment devices, and is concentrating its principal research and development activities in this field.」
The company continued its policy of concentrating research and development on high-value-added catheter-related products, artificial blood vessels and open stent grafts, among other products, and research and development expenses were ¥1.743 billion. - FY2020-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter were ¥1.3 billion. There were no material changes in the status of the group's research and development activities during the cumulative third quarter.」
The company disclosed that there were no material changes in its research and development policy and that cumulative research and development expenses for the third quarter were ¥1.3 billion. - FY2020-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter were ¥877 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter.」
The company stated that there were no material changes in research and development activities, and research and development expenses for the cumulative second quarter were ¥877 million. - FY2020-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter were ¥451 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter.」
There were no material changes in the research and development policy, and first-quarter research and development expenses were ¥451 million. - FY2019RestatedAnnual report
「The group aims to develop high-value-added disposable catheter products and their generators, console products, artificial blood vessels, open stent grafts and other products, and is concentrating its principal research and development activities in this field.」
The company continued its policy of concentrating research and development on high-value-added catheters, related equipment and artificial blood vessels, among other products, and research and development expenses for the fiscal year were ¥1.431 billion. - FY2019-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter were ¥1.091 billion. There were no material changes in the status of the group's research and development activities during the cumulative third quarter.」
The company stated that there were no material changes in research and development activities, and research and development expenses for the cumulative third quarter were ¥1.091 billion. - FY2019-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter were ¥777 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter.」
The company stated that there were no material changes in its research and development policy, and research and development expenses for the cumulative second quarter were ¥777 million. - FY2019-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter were ¥325 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter.」
The company stated that there were no material changes in its research and development policy, and disclosed first-quarter research and development expenses of ¥325 million. - FY2018RestatedAnnual report
「The group aims to develop high-value-added disposable catheter products and their generators, console products, artificial blood vessels, open stent grafts and other products, and is concentrating its principal research and development activities in this field.」
The company continued its policy of concentrating research and development on high-value-added disposable catheters, related equipment, artificial blood vessels and open stent grafts, and research and development expenses for the fiscal year were ¥1.121 billion. - FY2018-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter were ¥723 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter.」
The company stated that there were no material changes in research and development activities, and cumulative research and development expenses were ¥723 million. - FY2018-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter were ¥448 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter.」
The company stated that there were no material changes in research and development activities, and research and development expenses for the cumulative second quarter were ¥448 million. - FY2018-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter were ¥227 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter.」
Quarterly research and development expenses were ¥227 million, and the company stated that there were no material changes in the status of its research and development activities. - FY2017RestatedAnnual report
「We aim to develop high-value-added disposable catheter products and are concentrating our principal research and development activities in this field.」
There was no material change in the policy of concentrating research and development on high-value-added disposable catheters, and research and development expenses for the fiscal year were ¥1.051 billion. - FY2017-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter were ¥763 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter.」
There were no material changes in research and development activities, and cumulative research and development expenses were ¥763 million. - FY2017-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter were ¥473 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter.」
There were no material changes in research and development activities, and research and development expenses for the cumulative quarter were ¥473 million. - FY2017-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter were ¥254 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter.」
Research and development activities continued, with quarterly research and development expenses disclosed at ¥254 million. - FY2016First statedAnnual report
「We aim to develop high-value-added disposable catheter products and are concentrating our principal research and development activities in this field.」
The company is pursuing improvements to existing products using information from clinical settings and the development of high-quality, high-value-added products. Research and development expenses for the consolidated fiscal year were ¥933 million.